Watch a highlight reel of breast cancer data from ASCO 2026 that experts anticipate will have the biggest impact on the field.

Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.

Durable outcomes were reported standard-dose tivozanib monotherapy in second- and third-line metastatic RCC.

Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN Guidelines for select patients with previously treated breast cancer.

Darlifarnib plus cabozantinib showed durable responses and manageable safety in cabozantinib-naive advanced clear cell RCC.

A post-hoc analysis of LITESPARK-005 found that higher baseline and improved on-treatment QOL scores tracked with lower risk of disease progression and death.

Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.